SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors.

Grzelak, Ludivine; Temmam, Sarah; Planchais, Cyril; Demeret, Caroline; Huon, Christele; Guivel, Florence; Staropoli, Isabelle; Chazal, Maxime; Dufloo, Jeremy; Planas, Delphine; Buchrieser, Julian; Rajah, Maaran Michael; Robinot, Remy; Porrot, Francoise; Albert, Melanie; Chen, Kuang-Yu; Crescenzo, Bernadette; Donati, Flora; Anna, Francois; Souque, Philippe; Gransagne, Marion; Bellalou, Jacques; Nowakowski, Mireille; Backovic, Marija; Bouadma, lila; Le Fevre, Lucie; Le Hingrat, Quentin; Descamps, Diane; Pourbaix, Anabelle; Yazdanpanah, Yazdan; Tondeur, Laura; Besombes, Camille; Ungeheuer, Marie-Noelle; Mellon, Guillaume; Morel, Pascal; Rolland, Simon; Rey, Felix; Behillil, Sylvie; Enouf, Vincent; Lemaitre, Audrey; Creach, Marie-Aude; Petres, Stephane; Escriou, Nicolas; Charneau, Pierre; Fontanet, Arnaud; Hoen, Bruno; Bruel, Timothee; Eloit, Marc; Mouquet, Hugo; Schwartz, Olivier; van der Werf, Sylvie

It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their antibody response profile. Here, we performed a pilot study to assess the levels of anti-SARS-CoV-2 antibodies in samples taken from 491 pre- epidemic individuals, 51 patients from Hopital Bichat (Paris), 209 pauci-symptomatic individuals in the French Oise region and 200 contemporary Oise blood donors. Two in-house ELISA assays, that recognize the full-length nucleoprotein (N) or trimeric Spike (S) ectodomain were implemented. We also developed two novel assays: the S-Flow assay, which is based on the recognition of S at the cell surface by flow-cytometry, and the LIPS assay that recognizes diverse antigens (including S1 or N C- terminal domain) by immunoprecipitation. Overall, the results obtained with the four assays were similar, with differences in sensitivity that can be attributed to the technique and the antigen in use. High antibody titers were associated with neutralisation activity, assessed using infectious SARS-CoV- 2 or lentiviral-S pseudotypes. In hospitalized patients, seroconversion and neutralisation occurred on 5-14 days post symptom onset, confirming previous studies. Seropositivity was detected in 29% of pauci-symptomatic individuals within 15 days post-symptoms and 3 % of blood of healthy donors collected in the area of a cluster of COVID cases. Altogether, our assays allow for a broad evaluation of SARS-CoV2 seroprevalence and antibody profiling in different population subsets.